Lung fibroblast-derived extracellular vesicles and soluble factors alleviate elastase-induced lung injury

Saved in:
Bibliographic Details
Title: Lung fibroblast-derived extracellular vesicles and soluble factors alleviate elastase-induced lung injury
Authors: van der Koog, Luke, Boerrigter, Myrthe, Gorter, Iris, Gosens, Reinoud, Nagelkerke, Anika
Source: van der Koog, L, Boerrigter, M, Gorter, I, Gosens, R & Nagelkerke, A 2024, 'Lung fibroblast-derived extracellular vesicles and soluble factors alleviate elastase-induced lung injury', American Journal of Respiratory Cell and Molecular Biology, vol. 974, 176612. https://doi.org/10.1016/j.ejphar.2024.176612
Publication Year: 2024
Collection: University of Groningen research database
Subject Terms: Extracellular Vesicles/metabolism, Animals, Fibroblasts/drug effects, Pancreatic Elastase, Lung/pathology, Mice, Humans, Lung Injury/pathology, Cell Line, Male, Inbred C57BL, Disease Models, Animal, Solubility
Description: One of the main pathological features of chronic obstructive pulmonary disease (COPD) is the loss of functional alveolar tissue as a consequence of impaired regenerative capacities (emphysema). Recent research suggests that the secretome from mesenchymal cells, particularly extracellular vesicles (EVs), may possess regenerative properties beneficial for lung repair. However, the regenerative potential of the soluble factors (SFs) within the secretome remains largely unexplored in COPD. To this extent, we purified EVs and SFs secreted by lung fibroblasts to generate EV-enriched and SF-enriched fractions, and evaluated their effects on elastase-induced lung injury in both precision-cut lung slices (PCLS) and a mouse model. EV- and SF-enriched fractions were concentrated and purified from the conditioned medium of cultured MRC-5 lung fibroblasts using a combination of ultrafiltration and size exclusion chromatography, and were subsequently characterized according to the MISEV guidelines. Treatment with EV- or SF-enriched concentrates prevented and improved elastase-induced emphysema in PCLS, leading to reduced lung injury and upregulated markers of alveolar epithelial cells (aquaporin 5 and surfactant protein C), indicating potential parenchymal regeneration. Accordingly, prophylactic intratracheal treatment with lung fibroblast-derived EV- and SF-enriched concentrates in vivo attenuated elastase-induced lung tissue destruction, improved lung function, and enhanced gene expression of alveolar epithelial cell markers. Here, alveolar repair not only serves the purpose of facilitating gas exchange, but also by reinstating the essential parenchymal tethering required for optimal airway mechanics. In conclusion, this study highlights the therapeutic potential of both lung fibroblast-derived EV- and SF-enriched concentrates for the treatment of lung injury and emphysema.
Document Type: article in journal/newspaper
File Description: application/pdf
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/38677537; info:eu-repo/semantics/altIdentifier/hdl/https://hdl.handle.net/11370/2b070523-35e5-4e74-b515-09639b7879dd; info:eu-repo/semantics/altIdentifier/pissn/1044-1549; info:eu-repo/semantics/altIdentifier/eissn/1535-4989
DOI: 10.1016/j.ejphar.2024.176612
Availability: https://hdl.handle.net/11370/2b070523-35e5-4e74-b515-09639b7879dd
https://research.rug.nl/en/publications/2b070523-35e5-4e74-b515-09639b7879dd
https://doi.org/10.1016/j.ejphar.2024.176612
https://pure.rug.nl/ws/files/984152934/1-s2.0-S0014299924003005-main.pdf
https://www.scopus.com/pages/publications/85191286908
Rights: info:eu-repo/semantics/openAccess ; http://creativecommons.org/licenses/by/4.0/
Accession Number: edsbas.42EB3BC2
Database: BASE
Description
Abstract:One of the main pathological features of chronic obstructive pulmonary disease (COPD) is the loss of functional alveolar tissue as a consequence of impaired regenerative capacities (emphysema). Recent research suggests that the secretome from mesenchymal cells, particularly extracellular vesicles (EVs), may possess regenerative properties beneficial for lung repair. However, the regenerative potential of the soluble factors (SFs) within the secretome remains largely unexplored in COPD. To this extent, we purified EVs and SFs secreted by lung fibroblasts to generate EV-enriched and SF-enriched fractions, and evaluated their effects on elastase-induced lung injury in both precision-cut lung slices (PCLS) and a mouse model. EV- and SF-enriched fractions were concentrated and purified from the conditioned medium of cultured MRC-5 lung fibroblasts using a combination of ultrafiltration and size exclusion chromatography, and were subsequently characterized according to the MISEV guidelines. Treatment with EV- or SF-enriched concentrates prevented and improved elastase-induced emphysema in PCLS, leading to reduced lung injury and upregulated markers of alveolar epithelial cells (aquaporin 5 and surfactant protein C), indicating potential parenchymal regeneration. Accordingly, prophylactic intratracheal treatment with lung fibroblast-derived EV- and SF-enriched concentrates in vivo attenuated elastase-induced lung tissue destruction, improved lung function, and enhanced gene expression of alveolar epithelial cell markers. Here, alveolar repair not only serves the purpose of facilitating gas exchange, but also by reinstating the essential parenchymal tethering required for optimal airway mechanics. In conclusion, this study highlights the therapeutic potential of both lung fibroblast-derived EV- and SF-enriched concentrates for the treatment of lung injury and emphysema.
DOI:10.1016/j.ejphar.2024.176612